Myelodysplastic Syndromes Progress in Pathogenesis and Treatment

Key Points

• The aim is to explore the recent advances in the understanding and treatment of myelodysplastic syndromes (MDS).
• Overview of WHO 2022 and ICC classification systems for MDS.
• Discussion on new molecular classifications based on pattern recognition.
• Examination of treatments for low and high-risk MDS.
• Identification of genetic mutations enhances the classification of MDS.
• Introduction of TGF-β inhibitors shows promise for low-risk MDS.
• New drug developments for high-risk MDS are underway.
• Revised evaluation criteria for treatment efficacy in both low and high-risk groups.